Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches. Issue 12 (December 2019)

• Record Type: Journal Article
• Authors: Shribman, Samuel; Reid, Evan; Crosby, Andrew H; Houlden, Henry; Warner, Thomas T
• Is Part Of: Lancet neurology. Volume 18:Issue 12(2019)
• Page Start: 1136
• Page End: 1146
• Publication Date: 2019-12
• Subjects: Neurology -- Periodicals; Neurology -- Periodicals; Nervous System Diseases -- Periodicals; Neurologie -- Périodiques; Neurology; Electronic journals; Periodicals; 616.805
• DOI: 10.1016/S1474-4422(19)30235-2
• Languages: English
• ISSNs: 1474-4422

Abstract

Summary: Hereditary spastic paraplegia (HSP) describes a heterogeneous group of genetic neurodegenerative diseases characterised by progressive spasticity of the lower limbs. The pathogenic mechanism, associated clinical features, and imaging abnormalities vary substantially according to the affected gene and differentiating HSP from other genetic diseases associated with spasticity can be challenging. Next generation sequencing-based gene panels are now widely available but have limitations and a molecular diagnosis is not made in most suspected cases. Symptomatic management continues to evolve but with a greater understanding of the pathophysiological basis of individual HSP subtypes there are emerging opportunities to provide targeted molecular therapies and personalised medicine.